SBBP
Possible Long Targets Set For SBBPStrongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded on May 26, 2015 and is headquartered in Lower Southampton, PA.
SHORT INTEREST
1.13M 08/15/19
Average Recommendation: BUY
Average Target Price: 13.71
P/E Current
7.53
P/E Ratio (with extraordinary items)
6.21
P/E Ratio (without extraordinary items)
6.51
Large insider buying in SBBP starting on July 18thLarge insider buying in SBBP started on July 18th and more on July 23rd. Bullish signal!